MGEN Miragen Therapeutics Inc.

0.61
-0.05  -8%
Previous Close 0.66
Open 0.68
Price To Book 0.92
Market Cap 21,150,700
Shares 34,861,876
Volume 699,316
Short Ratio
Av. Daily Volume 564,829
Stock charts supplied by TradingView

NewsSee all news

  1. miRagen Announces Major Changes to Company's Strategy

    Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting in Q2 2020Focusing

  2. miRagen to Present at the Evercore ISI HealthCONx Conference 2019

    BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs,

  3. miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

    Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented restructuring to focus

  4. miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

    An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data released October 16, 2019.
MRG-110
Healthy volunteers
Phase 1 additional data presented April 26, 2019. Noted 4/5 patients remained stable for up to 16 months and continue on the trial.
Cobomarsen MRG-106
Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Cutaneous T-cell Lymphoma (CTCL); Adult T-Cell Leukemia/Lymphoma (ATLL)
Phase 2 interim data released December 11, 2019 - generally safe and well tolerated. Trial to continue through to primary endpoint.
MRG-201 Remlarsen
Keloids
Phase 2 data due 3Q 2020.
Cobomarsen - SOLAR
Cutaneous T-Cell Lymphoma

Latest News

  1. miRagen Announces Major Changes to Company's Strategy

    Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting in Q2 2020Focusing

  2. miRagen to Present at the Evercore ISI HealthCONx Conference 2019

    BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs,

  3. miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

    Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented restructuring to focus

  4. miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

    An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage